TRANSLATION AND LINGUISTIC VALIDATION OF THE FACT-EGFRI-18 FOR USE WITH CANCER PATIENTS WORLDWIDE

Author(s)

Parks-Vernizzi E, Debb SM, Savic L, Arnold B
FACITtrans, Elmhurst, IL, USA

OBJECTIVES: The purpose of this study was to translate and linguistically validate the FACT-EGFRI-18 scale into 22 languages - Arabic, Cebuano, Chinese (Simplified), Chinese (Traditional), French, German, Hebrew, Hungarian, Italian, Japanese, Korean, Malay, Polish, Portuguese, Russian, Romanian, Spanish, Tagalog, Tamil, Thai, Turkish, and Ukrainian for use in Belgium, Brazil, Canada, France, Germany, Hungary, India, Israel, Italy, Japan, Malaysia, Philippines, Poland, Portugal, Romania, Russia, Singapore, Spain, Thailand, Turkey, Ukraine, and USA. METHODS: The FACT-EGFRI-18 was translated based on the FACIT methodology: two forward translations, one reconciled version of the two forward translations, one back-translation into English, independent review, harmonization across languages, formatting and proofreading. Patients completed the FACT-EGFRI-18 questionnaire and participated in cognitive debriefing interviews to assess the relevance, understandability, and appropriateness of the translations. Qualitative analyses of subjects’ comments assessed the linguistic equivalence of each translated version. RESULTS: Total study sample consisted of 214 cancer patients (97 males and 117 females). The mean age of the sample was about 58 years. 199 patients were receiving treatment with EGFR inhibitors at the time of administration. The translated items were well understood by participants in each sample and were revised as needed if participants’ comments revealed misunderstanding of an item’s intended meaning. For example, the terms/phrases “embarrassed,” “irritated,” “skin condition,” “social life,” and “unattractive“ required alternative translation solutions to ensure cultural appropriateness, conceptual equivalence and harmonization in some languages. CONCLUSIONS: The FACT-EGFRI-18 has demonstrated linguistic validity across 22 languages. The translations are considered acceptable for PRO assessment in international research and clinical trials.

Conference/Value in Health Info

2016-05, ISPOR 2016, Washington DC, USA

Value in Health, Vol. 19, No. 3 (May 2016)

Code

PCN141

Topic

Patient-Centered Research

Topic Subcategory

Patient-reported Outcomes & Quality of Life Outcomes

Disease

Oncology

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×